Poland· PL-100411390
Baqsimi
A glucagon product containing glucagonum, registered in Poland by Amphastar France Pharmaceuticals. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Glucagon is registered in 17 of 19 countries.
Countries holding a registration under ATC H04AA01 (glucagon), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Glucagon · ATC H04AA01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of glucagon costs, country by country.
Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Glucagon · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$104.78
The record
At a glance
URPL (Poland)- Active substance
- Glucagonum
- Manufacturer
- Amphastar France Pharmaceuticals
- Country
- Poland (PL)
- ATC code
- H04AA01
- ATC class
- Glucagon
- Defined daily dose
- 3 mg, N
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05907677973109
- gtin03770033016046
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for glucagon.
Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glucagon · interactions on record
22 records
- 1 moderate
- 21 minor
Most severe, free to view
- IndometacinM01AB01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glucagon in 17 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBaqsimiSportpharm LLC
- FinlandBaqsimiAmphastar France Pharmaceuticals SAS
- CzechiaBAQSIMIAmphastar France Pharmaceuticals, Eragny Sur Epte
- CanadaBAQSIMIAMPHASTAR PHARMACEUTICALS, INC.
- SpainBAQSIMI 3 MG POLVO NASAL EN ENVASE UNIDOSISAmphastar France Pharmaceuticals
- BelgiumBaqsimi 3 mgAmphastar France Pharmaceuticals
- FranceBAQSIMI 3 mg, poudre nasale en récipient unidoseAMPHASTAR FRANCE PHARMACEUTICALS
- IrelandBaqsimi 3 mg nasal powder in single-dose containerAmphastar France Pharmaceuticals, S.A.S.
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Glucagen, Glucagen Hypokit
- Belgium · Glucagen, Glucagen Hypokit
- Bulgaria · Глюкаген Хипокит
- Cyprus · Glucagen Hypokit
- Czechia · Glucagen Hypokit
- Germany · Glucagen, Glucagen Hypokit
- Denmark · Glucagen, Glucagen Hypokit
- Estonia · Glucagen Hypokit
- Spain · Glucagen Hypokit
- Finland · Glucagen
- France · Glucagen, Glucagen Kit
- Greece · Glucagen, Glucagen Hypokit
- Croatia · Glucagen Hypokit
- Hungary · Glucagen Hypokit
- Ireland · Glucagen Hypokit
- Iceland · Baqsimi, Glucagen
- Italy · Glucagen, Glucagen Hypokit
- Liechtenstein · Baqsimi
- Lithuania · Glucagen Hypokit
- Luxembourg · Glucagen, Glucagen Hypokit
- Latvia · Glucagen Hypokit
- Malta · Glucagen, Glucagen Hypokit
- Netherlands · Glucagen, Hypokit
- Norway · Baqsimi, Glucagon
- Portugal · Glucagen, Glucagen Hypokit
- Romania · Glucagen Hypokit
- Sweden · Glucagon Novo Nordisk
- Slovenia · Glucagen Hypokit
- Slovakia · Glucagen Hypokit
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/717114e4-65d1-4a9a-a0cc-5c1088fd4022 GET /v1/drugs/717114e4-65d1-4a9a-a0cc-5c1088fd4022?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do nosa w pojemniku jednodawkowym",
"source": "urpl",
"strength": "3 mg",
"packaging": "05907677973109 ¦ Rp ¦ Skasowane ¦ EU/1/19/1406/001 ¦ 135080\n1 poj. 3 mg jednodawkowy\nRp ¦ EU/1/19/1406/002 ¦ 135081\n2 poj. 3 mg jednodawkowe\n03770033016046 ¦ Rp ¦ EU/1/19/1406/001 ¦ 160714\n1 poj. 3 mg jednodawkowy",
"substance": "Glucagoni hydrochloridum 3 mg",
"common_name": "Glucagonum",
"pl_product_id": "100411390",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about glucagon.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.